SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
The disclosure centers on the election of Charles Phillips as a director of Verizon, effective September 25, 2026. This is a clear appointment event — the principal action is a person taking a board role. While the filing mentions his participation in the standard non-employee director compensation program, the core event is the appointment itself, not a novel compensation arrangement.
View raw filing on EDGAR →Lexeo Therapeutics completed its acquisition of Mantle for upfront consideration of $5.3 million in cash and $3 million in Lexeo common stock, with contingent milestone payments up to $12 million over 12 years.
View raw filing on EDGAR →Canadian Pacific Kansas City Limited announced the issuance of CAD$1.8 billion in debt securities across four tranches (4.20% notes due 2030, 4.60% notes due 2033, 4.90% notes due 2037, and 5.40% notes due 2056) by its wholly-owned subsidiary Canadian Pacific Railway Company, guaranteed by the parent. The filing explicitly states the net proceeds will be used for refinancing outstanding indebtedness and general corporate purposes, which is a classic debt issuance disclosure under Item 8.01.
View raw filing on EDGAR →Phathom announced initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 clinical trial for VOQUEZNA in Non-Erosive GERD with an as-needed dosing regimen. This is a material operational and strategic milestone for a biopharmaceutical company—advancement of a key product candidate toward potential label expansion and regulatory submission. The disclosure does not fit narrower categories (not earnings, M&A, impairment, litigation, or governance), but is clearly a material clinical development event central to the company's pipeline strategy.
View raw filing on EDGAR →Kevin Shannon resigned from his position as Director of SL Investment Fund II LLC effective September 26, 2026. The disclosure centers on a director's departure, not an appointment or compensation arrangement. The filing explicitly states the resignation is not due to disagreement, but the departure itself is a material governance event affecting the board composition.
View raw filing on EDGAR →Kevin Shannon resigned from his position as a Director of T Series BDC LLC effective September 26, 2026. The disclosure centers on a director's departure, not an appointment or compensation arrangement. Director changes are material to investors as they affect governance and board composition.
View raw filing on EDGAR →Kevin Shannon resigned from his position as a Director of North Haven Private Income Fund LLC effective September 26, 2026. The disclosure centers on the departure itself—a director leaving the company—rather than any appointment or compensation arrangement. The filing explicitly states the resignation is not due to disagreement, but the departure of a board member is material to investors assessing governance and leadership continuity.
View raw filing on EDGAR →Heron Therapeutics entered into a multi-product Development and License Agreement with Long Grove Pharmaceuticals granting an exclusive license to import, distribute, sell and market certain products in the United States, with obligations to collaborate on development and commercialization. The agreement includes regulatory and sales-based milestone payments, royalties, and a ten-year initial term with automatic renewals. This represents a material acquisition of intellectual property rights and commercial rights that would affect a reasonable investor's assessment of the company's product pipeline and revenue potential.
View raw filing on EDGAR →Kevin Shannon resigned from his position as a Director of Morgan Stanley Direct Lending Fund effective September 26, 2026. The disclosure centers on the departure itself—a director leaving the board—which is a classic executive departure event. Director changes are material to investors assessing governance and board composition.
View raw filing on EDGAR →Kevin Shannon resigned from his position as a Director of North Haven Private Income Fund A LLC effective September 26, 2026. The disclosure centers on a director's departure, not an appointment or compensation arrangement. The filing explicitly states the resignation is not due to disagreement, but the departure itself is a material governance event affecting the board composition.
View raw filing on EDGAR →Kevin Shannon resigned from his position as a Director of LGAM Private Credit LLC effective September 26, 2026. The filing discloses a director departure with no disagreement cited. Director resignations are material governance events affecting the composition of the board and the registrant's leadership structure.
View raw filing on EDGAR →Item 5.02(e) discloses multiple compensatory arrangements: Dr. Sievers' consulting agreement with contingent payments up to $159,000 through June 2027; reinstatement of retention bonuses for CFO Vasquez ($148,888 target) and CEO Dr. Short ($440,892 target) contingent on December 31, 2026 milestones; and new performance bonuses for both executives ($75,000 and $220,000 targets respectively) contingent on March 31, 2027 milestones. While Dr. Sievers' resignation is mentioned, the filing's primary focus under Item 5.02(e) is the compensatory arrangements themselves, including the Board's approval of bonus programs and their terms.
View raw filing on EDGAR →Tectonic announced favorable Phase 1a safety and tolerability results for TX2100, along with FDA Fast Track designation and IND clearance for Phase 1b trials. This is a material clinical development milestone for a clinical-stage biotech company, representing significant progress in drug development. While not a traditional earnings release (the company is pre-revenue), the clinical trial results and regulatory approvals are operationally significant events that would affect investor assessment of the company's pipeline and development trajectory.
View raw filing on EDGAR →GEN Restaurant Group entered into a Common Stock Purchase Agreement with Roth Principal Investments granting the right to sell up to $25,000,000 of newly issued Class A common stock over 36 months (up to 6,776,399 shares, representing 19.99% of outstanding shares). The agreement includes registration rights and represents a registered direct offering mechanism with significant dilution potential.
View raw filing on EDGAR →Delek US Holdings completed a private offering of $460 million aggregate principal amount of 0.00% Convertible Senior Notes due 2031 on September 29, 2026. The senior unsecured notes, guaranteed by subsidiaries, were issued pursuant to an indenture with U.S. Bank Trust Company and sold to qualified institutional buyers under Rule 144A and Section 4(a)(2) exemptions. Proceeds will be used for partial repayment of the company's Term Loan Credit Facility, capped call transactions, and general corporate purposes.
View raw filing on EDGAR →The disclosure reports a material update on the proposed merger between MarketAxess and Intercontinental Exchange, Inc. Specifically, the parties voluntarily withdrew and refiled their Hart-Scott-Rodino premerger notifications on September 25 and September 29, 2026, respectively, extending the HSR Act waiting period to October 29, 2026. The filing confirms the merger remains subject to regulatory approval and stockholder vote, with completion expected in the first half of 2027. This is a substantive update to an ongoing material acquisition transaction.
View raw filing on EDGAR →Shareholders approved dissolution and liquidation of the company under a Plan of Complete Liquidation and Dissolution, and advisory approval of executive compensation in connection with the liquidation, at a Special Meeting held on September 29, 2026.
View raw filing on EDGAR →PRA Group announced the pricing of a $400.0 million offering of 8.500% senior notes due 2033 in a private transaction. This is a direct creation of a new financial obligation—issuance of debt securities—which is the core definition of debt_issuance. The company intends to use proceeds to repay existing revolving credit facility borrowings, representing a refinancing activity. The materiality is clear given the size ($400 million) and impact on the company's capital structure.
View raw filing on EDGAR →DBV Technologies announced submission of a Biologics License Application (BLA) to the FDA for VIASKIN® Peanut Patch in children aged 4-7 years, supported by successful Phase 3 VITESSE trial results and with Priority Review requested. This is a material regulatory milestone for a late-stage biopharmaceutical company advancing toward commercialization, but does not fit the specific categories of earnings release, M&A activity, or other named event types. It represents a significant operational/strategic advancement in the company's product development pipeline.
View raw filing on EDGAR →T1 Energy Inc. entered into a note purchase agreement on September 28, 2026 to sell $50.0 million in aggregate principal amount of convertible senior notes to a qualified institutional buyer. The convertible notes have an initial conversion price of approximately $4.46 per share (224.0143 shares per $1,000 principal amount), with a maximum of 13,440,860 shares of common stock potentially issuable upon conversion. The company is obligated to register the underlying shares for resale, and the proceeds are intended to finance Phase 1 of G2_Austin.
View raw filing on EDGAR →CID HoldCo entered into a Securities Purchase Agreement on September 25, 2026, to acquire 100% of Envoy Technologies' outstanding capital stock for $65 million in consideration (10,833,333 shares valued at $6.00 per share), representing a material acquisition that would constitute a change of control requiring stockholder approval under Nasdaq Rules 5635(a), (b) and (d). The transaction is explicitly disclosed under Item 1.01 and involves a definitive agreement with specified closing conditions and post-closing governance rights for the acquirer BladeRanger.
View raw filing on EDGAR →This is a press release announcing first-half 2026 financial results for One and One Green Technologies, disclosing revenues of $33.38 million (up 18.7%), net income of $4.49 million (up 17.4%), and detailed interim financial statements including balance sheet, income statement, and cash flow statement. The disclosure of interim period results through a press release is a classic earnings_release event, distinct from a periodic_interim report filing.
View raw filing on EDGAR →The 6-K discloses amendment and restatement of the Company's 2024 Share Incentive Plan, increasing the maximum aggregate share limit from 2,000,000 to 5,000,000 Ordinary Shares. This is a material modification to the equity compensation framework affecting director and officer compensation arrangements, approved by the Board and compensation committee on September 28, 2026. Such plan amendments are classified as executive compensation disclosures under Item 5.02(e) equivalent.
View raw filing on EDGAR →Meredith S. Manning was appointed as an independent director effective October 1, 2026, with assignment as Chairperson of the Nominating and Corporate Governance Committee, bringing extensive biopharmaceutical leadership and commercial expertise.
View raw filing on EDGAR →Unicycive announced the resubmission of a New Drug Application (NDA) for oxylanthanum carbonate with a new manufacturing vendor and updated CMC data, directly addressing prior FDA deficiencies and positioning the company for potential approval within 6 months of FDA acceptance.
View raw filing on EDGAR →The filing discloses amended appointment letters for three independent non-executive directors (Anthony S. Chan, Mau Chung Ng, and Mei Cai) that modify their compensatory arrangements effective October 1, 2026. The key change is the replacement of $20,000 per annum in share-based compensation with an equivalent cash payment, eliminating future equity issuances to these directors. This is a material modification to executive compensation arrangements, fitting squarely within the exec_compensation category.
View raw filing on EDGAR →Flash Sports & Media entered into a material definitive software development and technology services agreement with MindWave Innovations on September 28, 2026, for the design, development, and operation of FlashChain, a blockchain network for broadcasting rights and ticketing. The consideration includes $506,000 in common stock issuance and 20% of total FLASH TOKEN, representing a significant strategic commitment to blockchain infrastructure.
View raw filing on EDGAR →This is a press release announcing Turbo Energy's unaudited consolidated financial results for the six months ended June 30, 2026. The disclosure reports record revenue of €15.0 million (172.7% increase), a swing from operating loss to positive operating income of €510,542, and net income of €65,647. The exhibit includes condensed interim consolidated financial statements (income statement, balance sheet, and cash flows) and is material to investors assessing the registrant's financial performance and trajectory.
View raw filing on EDGAR →This press release announces two potential Japan projects with an estimated aggregate value of approximately $12 million that the Company expects to advance toward contracting in Q4 2026, with execution anticipated from mid-2027 through end of 2028. The disclosure is operational in nature—describing prospective business opportunities and strategic expansion in Japan—rather than a discrete event like M&A, earnings, or executive changes. While material to investors (representing significant future revenue visibility), the projects remain subject to further commercial discussions and definitive agreements, making this a forward-looking operational announcement rather than a completed transaction or financial event.
View raw filing on EDGAR →The 6-K discloses the consummation on September 28, 2025 of a subsequent offering of $3,000,000 in principal amount of senior secured convertible notes to an institutional buyer pursuant to a Securities Purchase Agreement. This constitutes creation of a new direct financial obligation (debt issuance) under Item 2.03 equivalent. The convertible feature and material principal amount make this material to investors assessing the registrant's capital structure and dilution risk.
View raw filing on EDGAR →The filing discloses Tessera's 2027 revenue targets ($14–16 million) and long-term targets through 2029 ($21 million in 2028, $30 million in 2029), along with a detailed growth strategy centered on scaling its physical security platform. While this is forward-looking guidance rather than reported results, it represents a material strategic disclosure of the company's commercial plan and expected financial trajectory. The Item 7.01 Regulation FD Disclosure format and the detailed operational milestones (70 platform deployments, 60 new customers, entry into 3 new geographies, etc.) indicate this is a significant operational and strategic announcement, not a routine administrative matter.
View raw filing on EDGAR →The filing discloses an unregistered issuance of TGL Shares valued at $500,000 to Mestiz Technology Sdn Bhd in satisfaction of a milestone under a software development agreement (Item 3.02). The company relied on Section 4(a)(2) and Regulation S exemptions from registration. While the primary Item 1.01 addresses a material contract amendment reducing scope and fees, the equity issuance component—particularly the potential for additional dilutive share issuances for the remaining $500,000 in service fees—is the material disclosure triggering Item 3.02 and represents a dilutive capital event.
View raw filing on EDGAR →This exhibit is an underwriting agreement dated September 23, 2026, for the issuance of US$1.3 billion in debt securities by Canadian Imperial Bank of Commerce: US$300 million in Floating Rate Senior Notes due 2030 and US$1 billion in 5.627% Fixed-to-Floating Rate Senior Notes due 2030. The agreement documents the creation of new direct financial obligations and is material to investors assessing the registrant's capital structure and leverage.
View raw filing on EDGAR →This is a press release announcing unaudited interim financial results for the six months ended June 30, 2026. The document explicitly states "EARNING RELEASE, DATED AS OF SEPTEMBER 29, 2026" and presents consolidated financial statements (balance sheet, income statement, comprehensive loss) with comparative prior-year figures. The company reports revenue of HK$77.2 million (down 6.0% YoY) and a net loss of HK$14.8 million (up 75.6% from prior-year loss of HK$8.5 million), driven by trade tensions and foreign exchange losses. This is a discrete earnings announcement, not a periodic financial report filing itself.
View raw filing on EDGAR →Maison Solutions received a formal notification from Nasdaq on September 23, 2026, stating non-compliance with Listing Rule 5250(c)(1) due to failure to timely file its Form 10-Q and Form 10-K. The company has until October 19, 2026 to submit a compliance plan, with potential delisting if the plan is not accepted or compliance is not achieved by February 9, 2027.
View raw filing on EDGAR →The 6-K discloses the closing of a private placement to "non-U.S. Persons" pursuant to a securities purchase agreement dated September 24, 2026, which closed on September 28, 2026. This is an unregistered sale of equity securities to foreign investors, a classic dilutive issuance event. The lack of detail on terms and amount does not diminish materiality—private placements to raise capital are material to investors assessing ownership dilution and the company's financing strategy.
View raw filing on EDGAR →Cadrenal Therapeutics held its 2026 Annual Meeting on September 24, 2026, with shareholders voting on five proposals: election of Class I director Quang X. Pham, ratification of WithumSmith+Brown as independent auditor, approval of Amendment No. 2 to the 2022 Successor Equity Incentive Plan (increasing share pool by 323,542 shares to 1,000,000 total), approval of warrant exercise issuance, and adjournment authority. The detailed voting results confirm shareholder approval of the equity plan amendment and dilutive warrant issuance.
View raw filing on EDGAR →Athena and Ace Green entered into a waiver to their Business Combination Agreement dated December 4, 2024, modifying key listing requirements for SPAC Warrants on Nasdaq. While technically a waiver rather than a new agreement, this materially amends the terms of the underlying business combination transaction and affects the structure of the post-merger entity's securities, making it a material modification to the M&A activity already in progress.
View raw filing on EDGAR →The 6-K discloses a material update to a previously announced acquisition: BitFuFu's acquisition of 51% of Uni-Titan LLC, which owns a 51-megawatt Bitcoin mining facility in Oklahoma. The filing reports completion of CFIUS review (dated September 28, 2026) with no unresolved national security concerns and execution of a national security agreement with U.S. government agencies. This represents a significant milestone in the acquisition transaction that would materially affect investor assessment of the company's capital deployment and operational capacity.
View raw filing on EDGAR →The filing discloses both a director resignation (Jaime Cosculluela, effective September 24, 2026) and the appointment of Marc Urbach to the Board on the same date. While both events are present, the substantive disclosure centers on Urbach's appointment—his background, independence determination, compensation terms ($12,000 quarterly base fee plus $3,000 chair fee), and the executed Board of Directors Agreement. The resignation is characterized as routine (personal reasons, no disagreement). The appointment of a new independent director with specified compensation is material to investors assessing board composition and governance.
View raw filing on EDGAR →Two directors—Jeffrey Goldberg and Carmen Volkart—have each provided written notice that they will not stand for re-election at the fiscal 2027 annual meeting. Although framed as non-standing for re-election rather than immediate resignation, this constitutes a departure of directors upon expiration of their current terms. The disclosures explicitly state that neither departure resulted from disagreement with the Company, indicating orderly transitions. The event is material because director changes affect governance and investor assessment of board composition.
View raw filing on EDGAR →Ebang acquired state-owned land use rights in Zhejiang Province for RMB 27.23 million (~$4 million) on September 28, 2026, intending to establish a manufacturing base for electrical power equipment and renewable energy products. This is a material operational and strategic expansion—a significant capital commitment to real property and manufacturing infrastructure—but does not fit the specific categories of M&A activity (no acquisition of a business entity or change of control), debt issuance, or other named event types. The disclosure emphasizes the Company's planned expansion of manufacturing operations and exploration of business opportunities in renewable energy and advanced manufacturing, making it a material operational/strategic event.
View raw filing on EDGAR →Ellomay Solar received a grid access and connection permit for a 22.2 MW / 100.3 MWh battery storage facility in Spain, representing a material operational and strategic milestone. The permit enables construction of a battery energy storage system (BESS) facility that the company identifies as "a core growth engine," with construction expected to commence in early 2027. This is a significant project development event that advances the company's renewable energy strategy but does not fit the specific categories of M&A, debt issuance, impairment, or other named event types.
View raw filing on EDGAR →The Company drew $5,000 thousand under an unsecured promissory note dated January 30, 2024 with Constellation Sponsor LP, creating a direct financial obligation. Although the note is unsecured and non-interest-bearing, it represents a material debt obligation that matures upon closing of the initial business combination. This is a creation of a direct financial obligation under Item 2.03, fitting the debt_issuance category as a drawdown on an existing credit facility or loan arrangement.
View raw filing on EDGAR →The filing discloses two 12-month technology services agreements entered into by MindWave Innovations (a subsidiary of Apimeds): one with AQUAE Holdings to deploy MindChain blockchain infrastructure for AQUAEChain (announced Sept 24, 2026) and one with Flash Sports & Media Holdings to build and operate FlashChain (announced Sept 29, 2026). Both involve material commercial contracts with consideration including software development fees, equity/token allocations, and ongoing technical services. These represent significant operational and strategic business developments for the company's blockchain infrastructure business, but do not fit neatly into M&A, debt, equity issuance, or other specific financial categories—they are material commercial partnerships and service contracts that expand the company's commercial footprint and revenue streams.
View raw filing on EDGAR →This is a press release dated September 29, 2026, announcing Baiya International Group Inc.'s unaudited financial results for the first half of fiscal year 2026 ended June 30, 2026. The exhibit contains consolidated balance sheets, statements of operations and comprehensive loss, and cash flow statements for the six-month period, along with management commentary from the CEO. This is a classic earnings release disclosing interim financial results, which is material to investors assessing the registrant's financial performance and condition.
View raw filing on EDGAR →Harvard Ave Acquisition Corp (SPAC) and OAG International Ltd entered into a definitive business combination agreement whereby OAG Merger Sub I will merge with HAVA and OAG Merger Sub II will merge with OAG, resulting in both becoming wholly-owned subsidiaries of newly formed PubCo with a $300 million valuation and expected Nasdaq listing.
View raw filing on EDGAR →The filing discloses Item 5.07 results from Citius Oncology's 2026 annual meeting of stockholders held on September 29, 2026, including election of three Class II directors (Dr. Eugene Holuka, Robert Smith, and Carol Webb) and ratification of Wolf & Company, P.C. as independent auditor, with specific vote tallies provided for each matter. This is a standard shareholder vote results disclosure that is material to investors as it reflects governance outcomes and auditor selection.
View raw filing on EDGAR →This disclosure describes a change of control of the Sponsor entity that holds approximately 80% of the Company's outstanding shares. Naoda Investments Limited transferred all its ordinary shares of the Sponsor to A SPAC (Holdings) Group Corp., resulting in a 100% ownership transfer of the Sponsor. This constitutes a material change in control of the registrant's parent entity and would significantly affect investor assessment of the Company's governance and control structure.
View raw filing on EDGAR →Enlivex disclosed that its ordinary shares are trading below the Nasdaq minimum bid price of $1.00 and face imminent delisting risk if the price remains below $1.00 for 30 consecutive trading days through October 21, 2026. The Company is seeking shareholder approval for a 1-for-16 reverse share split and amendment to its Articles of Association to address the delisting risk and restore compliance with Nasdaq listing standards.
View raw filing on EDGAR →